Search tips
Search criteria 


Logo of bmjThe BMJ
BMJ. 1993 October 9; 307(6909): 919–923.
PMCID: PMC1679037

Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party.


A working party of the British Society for Allergy and Clinical Immunology has reviewed the role of specific allergen immunotherapy in the treatment of allergic disease and produced a position statement summarising the available evidence for efficacy and safety. The working party recommends specific allergen immunotherapy for treating summer hay fever uncontrolled by conventional medication and for wasp and bee venom hypersensitivity. It is not recommended for asthma or for allergic rhinitis due to other allergens. For the recommended indications the risk:benefit ratio is acceptable provided patients are carefully selected; in particular, patients with asthma should be excluded as they are especially vulnerable to adverse reactions. Injections should be given only by doctors experiences in this form of treatment in a clinic where full resuscitative facilities are immediately available. Provided patients remain symptom free a 60 minute observation period after injection is sufficient to detect all serious adverse reactions.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Norman PS, Van Metre TE., Jr The safety of allergenic immunotherapy. J Allergy Clin Immunol. 1990 Feb;85(2):522–525. [PubMed]
  • Ortolani C, Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol. 1984 Feb;73(2):283–290. [PubMed]
  • Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 1991 Feb 2;302(6771):265–269. [PMC free article] [PubMed]
  • Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986 Feb;41(2):131–140. [PubMed]
  • Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990 Feb;85(2):460–472. [PubMed]
  • Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978 Oct 28;2(8096):912–915. [PubMed]
  • Blainey AD, Phillips MJ, Ollier S, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial. Allergy. 1984 Oct;39(7):521–528. [PubMed]
  • Bousquet J, Calvayrac P, Guérin B, Hejjaoui A, Dhivert H, Hewitt B, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol. 1985 Nov;76(5):734–744. [PubMed]
  • Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy. 1988 Sep;18(5):501–508. [PubMed]
  • Corrado OJ, Pastorello E, Ollier S, Cresswell L, Zanussi C, Ortolani C, Incorvaia A, Fugazza A, Lovely JR, Harris RI, et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis. 1. Clinical aspects. Allergy. 1989 Feb;44(2):108–115. [PubMed]
  • Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. J Allergy Clin Immunol. 1990 Sep;86(3 Pt 1):292–305. [PubMed]
  • Ewan PW. Allergy to insect stings: a review. J R Soc Med. 1985 Mar;78(3):234–239. [PMC free article] [PubMed]
  • Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigné R. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy. 1979 Dec;34(6):369–378. [PubMed]
  • Gillman SA, Cummins LH, Kozak PP, Jr, Hoffman DR. Venom immunotherapy: comparison of "rush" vs "conventional" schedules. Ann Allergy. 1980 Dec;45(6):351–354. [PubMed]
  • Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol. 1987 Jun;79(6):947–954. [PubMed]
  • Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Sundin B, Løwenstein H. Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol. 1986 Mar;77(3):488–496. [PubMed]
  • Sadan N, Rhyne MB, Mellits ED, Goldstein EO, Levy DA, Lichtenstein LM. Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med. 1969 Mar 20;280(12):623–627. [PubMed]
  • Sobotka AK, Valentine MD, Ishizaka K, Lichtenstein LM. Measurement of IgG-blocking antibodies: development and application of a radioimmunoassay. J Immunol. 1976 Jul;117(1):84–90. [PubMed]
  • Zeiss CR, Metzger WJ, Levitz D. Quantitative relationships between IgE antibody and blocking antibodies specific for antigen E in patients given immunotherapy with ragweed antigen E. Clin Exp Immunol. 1977 May;28(2):250–255. [PubMed]
  • Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol. 1982 Jun;69(6):489–493. [PubMed]
  • McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol. 1990 Oct;86(4 Pt 1):521–531. [PubMed]
  • Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990 Feb;85(2):473–479. [PubMed]

Articles from The BMJ are provided here courtesy of BMJ Publishing Group